By Benjamin Horney (February 12, 2015, 5:56 PM EST) -- Valeant Pharmaceuticals International Inc. is closing in on a deal to takeover fellow pharmaceutical company Salix Pharmaceuticals Ltd., Bloomberg reported on Thursday. According to the report, Valeant has arranged financing for the potential takeover, and could make a bid of more than $150 per share, which would value Salix at nearly $11 billion including debt. Rumors that Valeant has been considering making a play to scoop up Salix have run rampant since earlier this month. If Valeant does indeed wind up buying Salix, it would mark the company's first acquisition since reports said that Valeant's failed pursuit of Allergan Inc. led to its decision to scale back its acquisition activity in an attempt to reduce debt and bump up its stock price....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
